Cyteir Therapeutics to Participate in the Credit Suisse 30th Annual Healthcare Conference

Rhea-AI Summary

Cyteir Therapeutics, Inc. (NASDAQ: CYT) announced that its President and CEO, Markus Renschler, MD, will present at the Credit Suisse 30th Annual Healthcare Conference on November 8, 2021, at 4:20 PM ET. This virtual event will be accessible via a live webcast on the Cyteir website, with a replay available for 30 days post-event. Cyteir focuses on developing next-generation synthetically lethal cancer therapies, with its lead compound, CYT-0851, targeting RAD51-mediated homologous recombination to hinder DNA repair.

LEXINGTON, Mass.--(BUSINESS WIRE)-- Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that its President and Chief Executive Officer Markus Renschler, MD will participate in a presentation at the Credit Suisse 30th Annual Healthcare Conference, being held virtually on November 8, 2021, at 4:20pm ET.

A live webcast of the presentation will be available in the Investors & Media section of the Cyteir website at www.cyteir.com. A webcast replay will also be available on the website shortly after conclusion of the event for 30 days.

About Cyteir Therapeutics, Inc.

Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211101005062/en/

INVESTOR CONTACT:

Lisa Hayes

Vice President, Investor Relations and Corporate Communications

908-868-8926

Lisa.Hayes@cyteir.com

MEDIA CONTACT:

Michele Parisi

925-429-1850

mparisi@forwardhealthinc.com

Source: Cyteir Therapeutics

FAQ

When is Cyteir Therapeutics presenting at the Credit Suisse Healthcare Conference?

Cyteir Therapeutics will present on November 8, 2021, at 4:20 PM ET.

How can I watch the Cyteir Therapeutics conference presentation?

The presentation will be available through a live webcast on Cyteir's website.

What is the focus of Cyteir Therapeutics?

Cyteir Therapeutics specializes in developing next-generation synthetically lethal therapies for cancer.

What is the lead compound of Cyteir Therapeutics?

Cyteir's lead compound is CYT-0851, which inhibits RAD51-mediated homologous recombination.

Will there be a replay of the Cyteir Therapeutics presentation?

Yes, a replay of the presentation will be available on Cyteir's website for 30 days after the event.